– A multicenter, randomized, open-label phase 3 study to assess the efficacy of the combination of Sotorasib with a platinum doublet compared to the combination of Pembrolizumab with a platinum doublet as first-line therapy in participants with non-squamous, non-small cell lung cancer stage IV or advanced stage IIIB/C, PD-L1-negative and KRAS-p.G12C-positive (CodeBreak 202) Short title: A phase 3 study of first-line therapy with a platinum doublet in combination with Sotorasib versus Pembrolizumab in PD-L1-negative KRAS p.G12C-positive advanced/metastatic NSCLC (CodeBreaK 202)
Résumé de l'étude
This is an international, multicenter, randomized, open-label phase 3 study to evaluate the efficacy and safety of Sotorasib in combination with Carboplatin and Pemetrexed compared to Pembrolizumab in combination with Carboplatin and Pemetrexed in patients with stage IV or advanced stage IIIB/C NSCLC that is PD-L1 negative and KRAS p.G12C mutation positive. The study consists of a pre-treatment phase (pre-screening phase for patients with available molecular data and a screening phase), a treatment phase (4 platinum-containing cycles followed by a maintenance therapy), and a post-treatment phase (safety follow-up period [SFU] and long-term follow-up period [LTFU]). The target population of the study consists of patients with non-squamous NSCLC who are PD-L1 immunohistochemically (IHC) negative (TC or TPS<1%) and KRAS p.G12C mutation positive. Participants in the treatment group receiving Sotorasib (investigational product) will receive 960 mg of Sotorasib orally once daily in combination with Carboplatin under the concentration-time curve of 5 mg/ml/min and Pemetrexed 500 mg/m2, intravenously every 21 days for 4 cycles, followed by maintenance therapy (cycle 5 and beyond) with Sotorasib 960 mg PO and Pemetrexed 500 mg/m2 IV every 21 days. Patients in the Pembrolizumab treatment group (control) will receive Pembrolizumab 200 mg in combination with Carboplatin AUC5 and Pemetrexed 500 mg/m2, IV every 21 days for 4 cycles, followed by maintenance treatment (from cycle 5) with Pembrolizumab 200 mg IV (up to 35 cycles) and Pemetrexed 500 mg/m2 IV every 21 days. All participants will undergo an SFU assessment after the final discontinuation of the study treatment(s). After the SFU visit, long-term follow-up (LTFU) or the start of a new cancer therapy begins and lasts until the end of the study, until consent is withdrawn, or until death, whichever occurs first.
(BASEC)
Intervention étudiée
Participants will receive either oral Sotorasib at a daily dose of 960 mg in combination with Carboplatin (AUC5) and Pemetrexed 500 mg/m2 IV, or Pembrolizumab (200 mg) in combination with Carboplatin (AUC5) and Pemetrexed (500 mg/m2 IV) randomly. In both cases, the treatment cycle lasts 21 days and continues until disease progression, treatment intolerance, initiation of another cancer therapy, withdrawal of consent, or death.
(BASEC)
Maladie en cours d'investigation
PD-L1-negative KRAS p.G12C-positive advanced/metastatic NSCLC
(BASEC)
- histologically or cytologically confirmed diagnosis of NSCLC with non-squamous histology - stage IV or advanced stage IIIB/C NSCLC - no prior systemic cancer therapy for metastatic/unresectable disease - must provide a tumor tissue sample (or be willing to undergo a biopsy) for central molecular analysis - must be plasma-circulating tumor DNA (ctDNA) and/or tumor tissue positive for KRAS p.G12C mutation tested by the central laboratory (in selected cases local testing may be accepted) - must have measurable disease per RECIST v1.1 criteria - has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (BASEC)
Critères d'exclusion
- NSCLC with mixed histology and either small cell or large cell neuroendocrine component or predominant squamous cell histology - tumors known to have molecular alterations for which a targeted therapy is locally approved (including, but not limited to, EGFR or ALK alterations), except KRAS p.G12C - active brain metastases, defined as symptomatic (treated or untreated) brain metastases; participants with asymptomatic untreated brain metastases are eligible if they meet all predefined criteria - active autoimmune disease - evidence of active hepatitis B or C - known uncontrolled infection with human immunodeficiency virus (HIV), defined by detectable HIV concentration in blood and/or CD4 count below 400; known controlled HIV allowed (BASEC)
Lieu de l’étude
Aarau, Bâle, Zurich
(BASEC)
Sponsor
Amgen Inc. Thousand Oaks, CA, USA Amgen Switzerland AG, Rotkreuz
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. med. et Dr. phil. nat. Sacha Rothschild
+41 56 486 27 62
sacha.rothschild@clutterksb.chKantonsspital Baden
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
03.10.2023
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Phase 3 multicenter, randomized, open label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Patients with Stage IV and Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Positive for KRAS G12C. (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible